Cargando…

Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease

This concept article aims to show the rationale of targeting extracellular α-Synuclein (α-Syn) from cerebrospinal fluid (CSF) as a new strategy to remove this protein from the brain in Parkinson’s disease (PD). Misfolding and intracellular aggregation of α-synuclein into Lewy bodies are thought to b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menéndez-González, Manuel, Padilla-Zambrano, Huber S., Tomás-Zapico, Cristina, García, Benjamin Fernández
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Concept Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924388/ https://www.ncbi.nlm.nih.gov/pubmed/29570693 http://dx.doi.org/10.3390/brainsci8040052

Ejemplares similares

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis
por: Zhao, Hongli, et al.
Publicado: (2017)

Associations of sleep characteristics with alpha‐synuclein in cerebrospinal fluid in older adults
por: Wang, Xiao‐Tong, et al.
Publicado: (2020)

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders
por: Agnello, Luisa, et al.
Publicado: (2022)

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
por: Ibanez, Laura, et al.
Publicado: (2017)

Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
por: Menendez-Gonzalez, Manuel, et al.
Publicado: (2018)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Cerebrospinal Fluid Amyloid β(1-42), Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease
por: Kang, Ju-Hee
Publicado: (2016)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies
por: Perra, Daniela, et al.
Publicado: (2021)

Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011)

Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein
por: Dening, Yanina, et al.
Publicado: (2022)

9‐Membered Carbocycles: Strategies and Tactics for their Synthesis
por: Huber, Tatjana, et al.
Publicado: (2018)

Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease
por: Maass, Fabian, et al.
Publicado: (2020)

Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay
por: Cariulo, Cristina, et al.
Publicado: (2019)

“Anti‐electrostatic” Halogen Bonding between Ions of Like Charge
por: Holthoff, Jana M., et al.
Publicado: (2021)

Small Molecule Tools to Study Cellular Target Engagement for the Intracellular Allosteric Binding Site of GPCRs
por: Huber, Max E., et al.
Publicado: (2022)

Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022)

Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
por: Nwabufo, Chukwunonso K., et al.
Publicado: (2022)

Promising Therapeutic Approach for SARS‐CoV‐2 Infections by Using a Rutin‐Based Combination Therapy
por: Mazik, Monika
Publicado: (2022)

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease
por: Park, Min Jeong, et al.
Publicado: (2011)

α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK2‐linked Parkinson's disease
por: Garrido, Alicia, et al.
Publicado: (2019)

α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism
por: van Rumund, Anouke, et al.
Publicado: (2019)

Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease
por: Kang, Un Jung, et al.
Publicado: (2019)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson’s Disease
por: Shen, Ning, et al.
Publicado: (2019)

Transmission of alpha-synuclein in Parkinson’s disease
por: Lee, Virginia M-Y
Publicado: (2013)

Alpha-synuclein spreading in Parkinson’s disease
por: Recasens, Ariadna, et al.
Publicado: (2014)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease
por: Murakami, Hidetomo, et al.
Publicado: (2021)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α-Synuclein Levels in Parkinson's Disease: A Meta-Analysis
por: Zhou, Bo, et al.
Publicado: (2015)

α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients
por: Paslawski, Wojciech, et al.
Publicado: (2019)

Baseline concentration of misfolded α‐synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease
por: Ning, H., et al.
Publicado: (2018)

Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
por: Gómez-Benito, Mónica, et al.
Publicado: (2020)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)

Extracellular Alpha-Synuclein Oligomers Induce Parkin S-Nitrosylation: Relevance to Sporadic Parkinson’s Disease Etiopathology
por: Wilkaniec, Anna, et al.
Publicado: (2018)

Does TRODAT-1 SPECT Uptake Correlate with Cerebrospinal Fluid α-Synuclein Levels in Mid-Stage Parkinson’s Disease?
por: Coutinho, Artur M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2c2lluujq3i6r04l42336bdme8